Parexel and Paradigm Health Partner to Expand Access and Efficiency in Clinical Trials
Tuesday, September 16, 2025
Parexel, a global clinical research organisation (CRO), has formed a strategic partnership with Paradigm Health to transform how clinical trials are designed and executed. The collaboration aims to accelerate the delivery of new treatments by combining Parexel’s clinical expertise and worldwide reach with Paradigm Health’s AI-powered platform and network of healthcare providers.
The partnership introduces a technology-enabled trial execution model designed to improve efficiency, reduce costs, and increase patient access to clinical research. By integrating AI-driven optimisation into every stage of trial operations, the companies intend to overcome challenges linked to high costs, manual processes, and slow recruitment that often delay drug development.
With the average cost of bringing a new therapy to market exceeding $2 billion, biopharmaceutical companies face pressure to improve both time to market and operational performance. Through this alliance, Parexel will integrate Paradigm Health’s digital solutions and provider network into its service portfolio, allowing more patients to take part in trials as part of their routine care. This is expected to particularly benefit communities that have historically had limited access to innovative therapies.
The joint platform will enable faster recruitment, improved data quality, and lower monitoring costs, supporting both pharmaceutical and biotechnology sponsors. By delivering more efficient and representative clinical trials, the partnership aims to enhance outcomes for patients while easing the financial burden of drug development.
Source: globenewswire.com
